Denali Therapeutics said on Monday its experimental drug failed to meet the main goal of a mid-to-late stage trial involving patients with amyotrophic lateral sclerosis (ALS), a fatal ...

Denali Therapeutics said the latest trial of its treatment for amyotrophic lateral sclerosis, or ALS, didn't meet its primary or secondary endpoints after 24 weeks.

Primary endpoint of overall function (ALSFRS-R) and survival, and key secondary endpoints of muscle strength and respiratory function, were not ...

Denali Therapeutics said on Monday its experimental drug failed to meet the main goal of a mid-to-late stage trial in patients with amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative ...

Synchron announced today that it expanded its partnership with Team Gleason to raise awareness for its brain-computer ...

A Phase 1 trial testing RAG-17, a potential ALS therapy for people carrying SOD1 mutations, has dosed its first participant.

NeuroSense Therapeutics Ltd. ("NeuroSense"), a late-stage clinical biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that the Company received ...

Synchron, a brain-computer interface company, and Team Gleason, a foundation dedicated to improving the lives of people living with Amyotrophic Lateral Sclerosis (ALS), today announced an expanded ...

BCLI READ THE FULL BCLI RESEARCH REPORT Business Update Update on Planned Phase 3b Trial of NurOwn® in ALS On December 30, 2024, BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) conducted an investor ...

Thanks to awareness-raising initiatives like the Ice Bucket Challenge, we all have a better appreciation of amyotrophic ...

Chinese startup NeuroXess' new BCI can decipher the complex Chinese language in brain, operate a robotic arm and interact with AI.

The 4th annual Rally 4 Nally polar plunge took place on Saturday to raise awareness and donations for ALS. Rally 4 Nally, is ...